TELA Bio’s Hold Rating: Challenges in Sales Force Turnover and Financial Outlook

In a report released yesterday, Matthew O’Brien from Piper Sandler downgraded TELA Bio (TELA – Research Report) to a Hold, with a price target of $2.00.

Matthew O’Brien has given his Hold rating due to a combination of factors impacting TELA Bio’s performance and outlook. The company reported weaker-than-expected fourth-quarter results, with sales significantly below projections, attributed to substantial turnover in their sales force. This turnover has led to concerns about the company’s ability to meet its ambitious sales targets for 2025, especially with the need for new sales representatives to become productive quickly.
Additionally, TELA Bio’s management has provided guidance that falls short of previous expectations, requiring a steep increase in sales throughout the year. The company’s decision to maintain flat operating expenses could further strain resources, potentially affecting their ability to achieve revenue goals. Moreover, despite recent capital raising efforts, there is an anticipation of the need for additional financing, which could negatively impact the stock. These challenges collectively contribute to the Hold rating, as they present significant risks to the company’s near-term performance.

TELA’s price has also changed slightly for the past six months – from $2.590 to $2.340, which is a -9.65% drop .